New 'milestone' lung cancer treatment launches

Today sees the UK launch of nivolumab, a new treatment option 'milestone' for lung cancer patients with advanced or metastatic squamous non-small cell lung cancer (NSCLC), which affects a third of all lung cancer patients.

31 August 2015

In clinical trials, nivolumab has been shown to significantly improve survival outcomes for this group of patients. Nivolumab works by harnessing the ability of the immune system to find and fight cancer and is the first in a new class of medicines - immune checkpoint inhibitors - to be approved for lung cancer.

Dr Sanjay Popat, Consultant Thoracic Medical Oncologist in The Royal Marsden's Lung Unit, is the UK Chief Investigator of a trial of nivolumab in relapsed patients with advanced squamous type NSCLC, set to open in the next few weeks. He said: "I am delighted that patients with squamous-type lung cancer will get access to treatment with nivolumab in this trial, for which The Royal Marsden is the lead UK research site."

Find out more

For more information about this or any other news story, contact The Royal Marsden Press Office.